Judge nixes a Biden rule in order to keep medical debt on credit reports

A federal judge has vacated a Biden-era Consumer Financial Protection Bureau (CFPB) rule that would have removed an estimated $49 billion in medical debt from credit reports for approximately 15 million Americans. The court ruled the CFPB exceeded its authority under the Fair Credit Reporting Act, siding with industry associations and the Trump administration who argued the rule would compromise credit report accuracy and underwriting processes. This decision means medical debt will continue to be a factor in consumer credit profiles and lending decisions, preventing the credit score boosts and increased mortgage approvals the rule aimed to facilitate, despite CFPB research indicating medical debt is not a strong predictor of repayment ability.

Analysis

A federal court ruling has vacated a key Consumer Financial Protection Bureau (CFPB) rule, preventing the mandated removal of an estimated $49 billion in medical debt from the credit reports of 15 million Americans. The court found the CFPB exceeded its authority, a decision that represents a significant victory for the credit reporting industry, including firms like Equifax (EFX), TransUnion (TRU), and Fair Isaac Corp (FICO), as reflected in their positive per-ticker sentiment scores. The ruling averts a scenario where lenders would have lost a data point they argue is critical for accurate underwriting, thereby preventing the forced approval of what the CFPB estimated would be 22,000 additional mortgages annually. While proponents argued the rule would provide an average 20-point credit score boost to affected consumers, industry groups and Republican lawmakers contended it would weaken credit report accuracy and increase systemic risk. It is important to note, however, that the three major credit bureaus have already voluntarily taken steps to reduce the impact of medical debt, such as removing paid collections, ignoring debts under $500, and extending the grace period to one year, thereby already moderating the data's effect on consumer credit profiles.

Key Decisions for Investors

• View this ruling as a positive development for credit bureaus like Equifax (EFX) and TransUnion (TRU), as it removes a significant regulatory headwind and reinforces the value of their comprehensive data sets for underwriting.
• Investors in the financial and lending sectors should recognize that the retention of medical debt data supports existing, more conservative risk assessment models, preventing a mandated loosening of credit standards.
• Monitor for potential future legislative action from Congress, as the court's rationale explicitly frames this issue as a matter for lawmakers, suggesting the debate over medical debt's role in credit scoring will persist.
• Acknowledge that the industry's prior voluntary actions to minimize the impact of medical debt mean this ruling largely preserves the current, moderated status quo rather than reverting to a more punitive system.